Search details
1.
Representation of Racial and Ethnic Minorities in Nephrology Clinical Trials: A Systematic Review and Meta-Analysis.
J Am Soc Nephrol
; 34(7): 1167-1177, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-37022114
2.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Am J Kidney Dis
; 82(1): 84-96.e1, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36889425
3.
Chronic kidney disease and risk of kidney or urothelial malignancy: systematic review and meta-analysis.
Nephrol Dial Transplant
; 2023 Nov 30.
Article
in English
| MEDLINE | ID: mdl-38037426
4.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab
; 25(8): 2151-2162, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37161691
5.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation
; 143(18): 1735-1749, 2021 05 04.
Article
in English
| MEDLINE | ID: mdl-33554616
6.
A randomized controlled pilot trial of anakinra for hemodialysis inflammation.
Kidney Int
; 102(5): 1178-1187, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35863559
7.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med
; 380(24): 2295-2306, 2019 06 13.
Article
in English
| MEDLINE | ID: mdl-30990260
8.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Am J Kidney Dis
; 79(2): 244-256.e1, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34029680
9.
Effect of Normalizing eGFR to Standard Body Surface Area on Rates of Obesity-Related Hyperfiltration among Diverse Female Adolescents.
Am J Nephrol
; 53(4): 282-289, 2022.
Article
in English
| MEDLINE | ID: mdl-35378531
10.
Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting.
J Ren Nutr
; 32(4): e1-e14, 2022 07.
Article
in English
| MEDLINE | ID: mdl-34364782
11.
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia.
J Am Soc Nephrol
; 32(8): 2020-2030, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34244326
12.
AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.
J Am Soc Nephrol
; 32(1): 161-176, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33067383
13.
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Eur Heart J
; 42(48): 4891-4901, 2021 12 21.
Article
in English
| MEDLINE | ID: mdl-34423370
14.
Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment.
Circulation
; 141(1): 21-33, 2020 01 07.
Article
in English
| MEDLINE | ID: mdl-31779467
15.
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Kidney Int
; 99(4): 999-1009, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33316282
16.
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Am Heart J
; 233: 141-148, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33358942
17.
Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces.
Curr Opin Nephrol Hypertens
; 30(2): 198-207, 2021 03 01.
Article
in English
| MEDLINE | ID: mdl-33395034
18.
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
Diabetes Obes Metab
; 23(7): 1652-1659, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33769679
19.
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
J Am Soc Nephrol
; 31(12): 2925-2936, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32998938
20.
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
J Am Soc Nephrol
; 31(5): 1128-1139, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32354987